Value20212022202320242025TTMSelling/general/admin expenses———26.88 M22.34 M21.69 MResearch & development———67.88 M67.75 M56.06 MOperating income———-63.32 M-91.08 M-78.41 MNon-Operating Income, Total———5.12 M-4.99 M-2.1 MInterest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses———646 K-8.47 M-5.18 MUnusual income/expense———4.47 M3.48 M3.08 MPretax income———-44.46 M-88.6 M-75.03 MEquity in earnings——————Taxes———845 K11 K11 KNon-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations———-45.31 M-88.61 M-75.04 MDiscontinued operations——————Net income———-45.31 M-88.61 M-75.04 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders———-45.31 M-88.61 M-75.04 MBasic earnings per share (Basic EPS)———-0.33-0.63-0.54Diluted earnings per share (Diluted EPS)———-0.33-0.63-0.54Average basic shares outstanding———138.75 M141.69 M—Diluted shares outstanding———138.75 M141.69 M—EBITDA———5.16 M-22.77 M-23.14 MEBIT———4.56 M-23.32 M-23.67 MCost of revenue———11.81 M215 K172 KOther cost of goods sold——————Depreciation & amortization (cash flow)———593 K555 K523 K
Silence Therapeutics Plc - American Depository Share
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.